The Innovative Support for Patients with SARS COV-2 Infections Registry (INSPIRE) study is a CDC-funded COVID-19 project to understand the long-term health outcomes in recently tested adults, both negative and positive, who have suspected COVID symptoms at the time of their test. Participants will complete short online surveys every 3 months for 18 months, share information about their health using a secure web-based platform, and are compensated for their time.
This study will use a digital platform to longitudinally track comprehensive information including patient self-report as well as data that describe the process and outcome of care in the electronic medical record (EMR) of a large representative sample of patients under investigation for SARSCOV2. The objective is to generate knowledge rapidly using digital tools and collaborative sciences to produce real-time data, analysis, and reporting compared to more traditional approaches. An additional goal is to promote an open science approach whereby scientists, with proper approvals and in line with the permissions granted by the participants, have the opportunity to work with data in ways that protect individual privacy but promote rapid dissemination and implementation of knowledge.
Study Type
OBSERVATIONAL
Enrollment
6,000
UCLA
Los Angeles, California, United States
UCSF
San Francisco, California, United States
Yale
New Haven, Connecticut, United States
Rush University Medical Center
Chicago, Illinois, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Texas Southwestern
Dallas, Texas, United States
University of Texas Health Science Center at Houston
Houston, Texas, United States
University of Washington
Seattle, Washington, United States
Assess for medium and long-term sequalae of SARS-CoV-2 infection
Clinical phenotypes of sequelae will be determined at the time of analysis based on published literature
Time frame: 18 months post enrollment
Incident myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Determine the risk of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in those with symptoms of SARSCOV2 infection with vs. without a positive confirmatory test.
Time frame: 18 months post enrollment
Ambulatory care and/or ED visits post enrollment
Count of ambulatory care and/or ED visits post enrollment as obtained from the EMR
Time frame: 18 months post enrollment
Hospitalizations post enrollment
Count of hospitalizations post enrollment as obtained from the EMR
Time frame: 18 months post enrollment
Death during hospital admission
Death during hospital admission as determined by data from the EMR
Time frame: 18 months post enrollment
Hospital-free survival
Hospital-free survival as determined by data from the EMR
Time frame: 18 months post enrollment
ICU-free survival
ICU-free survival as determined by data from the EMR
Time frame: 18 months post enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.